Histone Deacetylase Inhibitor LAQ824 Augments Inflammatory Responses in Macrophages through Transcriptional Regulation of IL-10

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Journal of Immunology

• Publication date

  2011-04-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.4049/jimmunol.1001101PMID 21368229PMCID PMC3998678
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The regulation of IL-10 production by immune cells

  2010cited by this paper
• The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance

  2009cited by this paper
• From immunity to tolerance through HDAC

  2009cited by this paper
• Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges.

  2009cited by this paper
• Enhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824.

  2009cited by this paper
• A20 is an antigen presentation attenuator, and its inhibition overcomes regulatory T cell–mediated suppression

  2008cited by this paper
• Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces.

  2008cited by this paper
• Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase-dependent DC functions and regulates experimental graft-versus-host disease in mice.

  2008cited by this paper
• The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men

  2008cited by this paper
• Histone deacetylase regulation of immune gene expression in tumor cells

  2008cited by this paper
• Contextual regulation of inflammation: a duet by transforming growth factor-beta and interleukin-10.

  2008cited by this paper
• Immunosuppressive strategies that are mediated by tumor cells.

  2007cited by this paper
• Discovery and development of SAHA as an anticancer agent

  2007cited by this paper
• Identification of a novel negative role of flagellin in regulating IL‐10 production

  2007cited by this paper
• Histone deacetylases and cancer

  2007cited by this paper
• Gene-specific control of inflammation by TLR-induced chromatin modifications

  2007cited by this paper
• Cellular and molecular mechanisms of tumor-induced T-cell tolerance.

  2007cited by this paper
• Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies.

  2006cited by this paper
• Histone Hyperacetylation Is Associated with Amelioration of Experimental Colitis in Mice1

  2006cited by this paper
• Epigenetic regulation of immune escape genes in cancer

  2006cited by this paper
• Dynamic and Transient Remodeling of the Macrophage IL-10 Promoter during Transcription1

  2006cited by this paper
• Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors

  2005cited by this paper
• Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1–polarizing program in dendritic cells

  2005cited by this paper
• Interleukin (IL)-4 inhibits IL-10 to promote IL-12 production by dendritic cells

  2005cited by this paper
• ERK Activation Following Macrophage FcγR Ligation Leads to Chromatin Modifications at the IL-10 Locus1

  2005cited by this paper
• SOCS1 restricts dendritic cells' ability to break self tolerance and induce antitumor immunity by regulating IL-12 production and signaling.

  2005cited by this paper
• Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis.

  2005cited by this paper
• Metastatic melanoma secreted IL-10 down-regulates CD1 molecules on dendritic cells in metastatic tumor lesions.

  2004influential reference
• Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect.

  2004cited by this paper
• Chromatin-level Regulation of the IL10 Gene in T Cells*

  2004cited by this paper
• Th1/Th2 balance in cancer, transplantation and pregnancy

  2004cited by this paper
• Direct association between PU.1 and MeCP2 that recruits mSin3A-HDAC complex for PU.1-mediated transcriptional repression

  2003cited by this paper
• T cell anergy.

  2003cited by this paper
• A critical role for Stat3 signaling in immune tolerance.

  2003cited by this paper
• Extra-lymphatic solid tumor growth is not immunologically ignored and results in early induction of antigen-specific T-cell anergy: dominant role of cross-tolerance to tumor antigens.

  2003cited by this paper
• Collaborative spirit of histone deacetylases in regulating chromatin structure and gene expression.

  2003cited by this paper
• Tolerogenic dendritic cells.

  2003cited by this paper
• Does the immune system see tumors as foreign or self?

  2003cited by this paper
• Antigen presentation and T cell stimulation by dendritic cells.

  2002cited by this paper
• Potential Regulatory Function of Human Dendritic Cells Expressing Indoleamine 2,3-Dioxygenase

  2002cited by this paper
• Differential regulation of interleukin-10 production by genetic and environmental factors – a twin study

  2002cited by this paper
• A new mathematical model for relative quantification in real-time RT-PCR.

  2001cited by this paper
• Interleukin-10 and the interleukin-10 receptor.

  2001cited by this paper
• Cross-presentation of tumor antigens by bone marrow-derived antigen-presenting cells is the dominant mechanism in the induction of T-cell tolerance during B-cell lymphoma progression.

  2001cited by this paper
• IL-10 Gene Expression Is Controlled by the Transcription Factors Sp1 and Sp31

  2000cited by this paper
• Role of Stat3 in Lipopolysaccharide-Induced IL-10 Gene Expression1

  2000cited by this paper
• Induction of antigen-specific T cell anergy: An early event in the course of tumor progression.

  1998cited by this paper
• Interleukin‐10 prevents the generation of dendritic cells from human peripheral blood mononuclear cells cultured with interleukin‐4 and granulocyte/ macrophage‐colony‐stimulating factor

  1997influential reference
• Interleukin-10 induces a long-term antigen-specific anergic state in human CD4+ T cells

  1996cited by this paper
• Naive CD4+ T cells confer idiotype‐specific tumor resistance in the absence of antibodies

  1995cited by this paper
• Thymic selection of CD8+ single positive cells with a class II major histocompatibility complex-restricted receptor

  1994cited by this paper
• Role of tumor-derived cytokines on the immune system of mice bearing a mammary adenocarcinoma. II. Down-regulation of macrophage-mediated cytotoxicity by tumor-derived granulocyte-macrophage colony-stimulating factor.

  1991cited by this paper

• HDAC11 deficiency improves muscle phenotype in a Duchenne muscular dystrophy murine model by reducing inflammation and fibrosis.

  2025cites this paper
• Targeting hormone-related signals to reprogram the antitumor immune response in breast cancer: Research progress and application prospects.

  2025cites this paper
• HDAC11 deficiency regulates age-related muscle decline and sarcopenia

  2025cites this paper
• Histone Deacetylase Inhibitors Directly Modulate T Cell Gene Expression and Signaling and Promote Development of Effector-Exhausted T Cells in Murine Tumors.

  2024cites this paper
• The impact of histone deacetylase inhibitors on immune cells and implications for cancer therapy.

  2023cites this paper
• CC-01 (chidamide plus celecoxib) modifies the tumor immune microenvironment and reduces tumor progression combined with immune checkpoint inhibitor

  2022cites this paper
• Differentiation of crescent-forming kidney progenitor cells into podocytes attenuates severe glomerulonephritis in mice

  2022cites this paper
• Entinostat, a histone deacetylase inhibitor, increases the population of IL-10+ regulatory B cells to suppress contact hypersensitivity

  2021cites this paper
• Enhancing Therapeutic Approaches for Melanoma Patients Targeting Epigenetic Modifiers

  2021cites this paper
• Anti-inflammatory role of Gpnmb in adipose tissue of mice

  2021cites this paper
• Preclinical and clinical progress for HDAC as a putative target for epigenetic remodeling and functionality of immune cells

  2021cites this paper
• Inhibiting Histone Deacetylases in Human Macrophages Promotes Glycolysis, IL-1β, and T Helper Cell Responses to Mycobacterium tuberculosis

  2020cites this paper
• Loss of HDAC11 accelerates skeletal muscle regeneration in mice

  2020cites this paper
• Histone Deacetylase 11 Contributes to Renal Fibrosis by Repressing KLF15 Transcription

  2020cites this paper
• Marine-Derived Secondary Metabolites as Promising Epigenetic Bio-Compounds for Anticancer Therapy

  2020cites this paper
• Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 To Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution

  2020cites this paper
• Histone Deacetylation Inhibitors as Therapy Concept in Sepsis

  2019influential citation
• Histone Deacetylase Inhibitors in Tumor Immunotherapy.

  2019cites this paper
• Regulation of Chemokines and Cytokines by Histone Deacetylases and an Update on Histone Decetylase Inhibitors in Human Diseases

  2019cites this paper
• Post-Translational Modifications in NETosis and NETs-Mediated Diseases

  2019cites this paper
• HDAC inhibitors as epigenetic regulators for cancer immunotherapy.

  2018cites this paper
• Turn Back the TIMe: Targeting Tumor Infiltrating Myeloid Cells to Revert Cancer Progression

  2018cites this paper
• Epigenetic control of macrophage polarization: implications for targeting tumor-associated macrophages

  2018influential citation
• HDAC11 is a regulator of diverse immune functions.

  2018cites this paper
• REOVIRUS-DRIVEN MYELOID CELLS IN ONCOLYTIC VIRUS THERAPY AND INFECTION

  2018cites this paper
• Targeted Therapy and Immunosuppression in the Tumor Microenvironment.

  2017cites this paper
• Examining a role for histone deacetylase inhibitors asimmunosuppressants in organ transplantation

  2016cites this paper
• Histone deacetylases in monocyte/macrophage development, activation and metabolism: refining HDAC targets for inflammatory and infectious diseases

  2016cites this paper
• Histone Deacetylases

  2016cites this paper
• Functional Analysis of Histone Deacetylase 11 (HDAC11).

  2016cites this paper
• Alteration in the concentrations of Interleukin-7 (IL-7), Interleukin-10 (IL-10) and Granulocyte Colony Stimulating Factor (G-CSF) in alcohol-dependent individuals without liver disease, during detoxification therapy.

  2016cites this paper
• Histone deacetylase 3 (HDAC 3) as emerging drug target in NF-κB-mediated inflammation.

  2016cites this paper
• Iron oxide nanoparticles inhibit tumour growth by inducing pro-inflammatory macrophage polarization in tumour tissues.

  2016cites this paper
• Epigenetic Control of Macrophage Polarisation and Soluble Mediator Gene Expression during Inflammation

  2016cites this paper
• Molecular signatures of mu opioid receptor and somatostatin receptor 2 in pancreatic cancer

  2016cites this paper
• The role of myeloid cells in cancer therapies

  2016cites this paper
• Differential Anti-inflammatory Activity of HDAC Inhibitors in Human Macrophages and Rat Arthritis

  2016cites this paper
• Transcriptomic changes throughout post-hatch development in Gallus gallus pituitary

  2016cites this paper
• Exploration of the chicken (Gallus gallus) pituitary gland transcriptome

  2016cites this paper
• Modulation of antitumor immunity by the MEK inhibitor trametinib: Implications for targeted therapy of cancer

  2016cites this paper
• NRSF is an essential mediator for the neuroprotection of trichostatin A in the MPTP mouse model of Parkinson's disease.

  2015cites this paper
• Nonviral Oncogenic Antigens and the Inflammatory Signals Driving Early Cancer Development as Targets for Cancer Immunoprevention

  2015cites this paper
• Knockout of Angiotensin AT2 receptors accelerates healing but impairs quality

  2015cites this paper
• Regulation of the Jak/STATs Pathways by Histone Deacetylases

  2014cites this paper
• Pathway in APCs Regulation of the Tolerogenic STAT3/IL-10 A Novel Role for Histone Deacetylase 6 in the

  2014cites this paper
• HDAC inhibitors and immunotherapy; a double edged sword?

  2014influential citation
• A Novel Role for Histone Deacetylase 6 in the Regulation of the Tolerogenic STAT3/IL-10 Pathway in APCs

  2014cites this paper
• Histone deacetylase inhibitors suppress immune activation in primary mouse microglia

  2013cites this paper
• The antimelanoma activity of the histone deacetylase inhibitor panobinostat (LBH589) is mediated by direct tumor cytotoxicity and increased tumor immunogenicity

  2013cites this paper
• Epigenetic Approaches: Emerging Role of Histone Deacetylase Inhibitors in Cancer Immunotherapy

  2013cites this paper
• Histone Deacetylases as Targets for Melanoma Immunotherapy

  2013cites this paper
• Caractérisation des sirtuines de Schistosoma mansoni : cibles thérapeutiques potentielles

  2013cites this paper
• Histone deacetylase inhibitor suppresses virus-induced proinflammatory responses and type 1 diabetes

  2013cites this paper
• LBH589 enhances T cell activation in vivo and accelerates graft-versus-host disease in mice.

  2012cites this paper
• Histone deacetylase inhibitors in the generation of the anti‐tumour immune response

  2012cites this paper
• Rôle de l’acétylation/déacétylation des histones dans la régulation de l’expression des gènes de la COX-2, iNOS et mPGES-1 dans les tissus articulaires

  2012influential citation
• Selective histone deacetylase 6 inhibitors bearing substituted urea linkers inhibit melanoma cell growth.

  2012cites this paper
• Modulation of antigen‐presenting cells by HDAC inhibitors: implications in autoimmunity and cancer

  2012cites this paper
• HDACi: molecular mechanisms and therapeutic implications in the innate immune system

  2012cites this paper
• Histone Deacetylase Inhibitors for Treating a Spectrum of Diseases Not Related to Cancer

  2011cites this paper
• Function of histone deacetylase inhibitors in inflammation.

  2011cites this paper